CytomX Therapeutics Announces Proposed Public Offering of Common Stock
2021年1月20日 - 6:35AM
CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage,
oncology-focused biopharmaceutical company with a vision of
transforming lives with safer, more effective therapies, today
announced that it has commenced an underwritten public offering of
$75.0 million of its common stock. In addition, CytomX expects to
grant the underwriters a 30-day option to purchase up to an
additional $11.25 million of its common stock at the public
offering price, less underwriting discounts and commissions. The
offering is subject to market and other conditions, and there can
be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering. All
of the shares are to be offered by CytomX.
CytomX expects to use the net proceeds from this offering to
further develop its proprietary Probody® therapeutics pipeline and
research. In particular, CytomX expects to use the net proceeds,
together with existing cash resources, to fund: (i) the advancement
and expansion of the clinical development program for CX-2009,
including the ongoing Phase 2 study of CX-2009 as monotherapy and
in combination with CX-072 in breast cancer; (ii) the advancement
and expansion of the clinical development program for CX-2029,
including the ongoing Phase 2 study of CX-2029 in four types of
cancer; (iii) IND enabling studies for CX-2043 and CX-904, their
IND submissions and Phase 1 clinical development; and (iv) further
research and development activities related to our Probody
platform, the tumor microenvironment, new drug candidates and
translational sciences. CytomX expects to use any
remaining net proceeds from this offering for capital expenditures,
working capital and other general corporate purposes.
J.P. Morgan Securities LLC, Cowen & Company, LLC and Piper
Sandler & Co. are acting as joint bookrunning managers for the
offering.
The securities are being offered pursuant to a registration
statement that was filed with the Securities and Exchange
Commission (“SEC”) on November 6, 2018, amended on February 6,
2019, and was declared effective on February 11, 2019. A
preliminary prospectus supplement relating to and describing the
terms of the offering was filed with the SEC on January 19, 2021
and is available on the SEC’s website at www.sec.gov. Copies of the
preliminary prospectus supplement and the accompanying prospectus
relating to these securities may also be obtained for free from:
J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, New York 11717, telephone:
1-866-803-9204, or by emailing at prospectus-eq_fi@jpmchase.com;
Cowen & Company, LLC, c/o Broadridge Financial Solutions, 1155
Long Island Avenue, Edgewood, NY 11717, via telephone: +1 (833)
297-2926, or via email: PostSaleManualRequests@broadridge.com; and
Piper Sandler & Co., Attention: Prospectus Department, 800
Nicollet Mall, J12S03, Minneapolis, MN 55402, or by telephone at
800-747-3924, or by email at prospectus@psc.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation, or sale would be unlawful prior to registration or
qualification of these securities under the securities laws of any
such state or jurisdiction.
About CytomX Therapeutics
CytomX is a clinical-stage, oncology-focused biopharmaceutical
company with a vision of transforming lives with safer, more
effective therapies. The Company is developing a novel class of
investigational antibody therapeutics, based on our Probody®
technology platform, for the treatment of cancer. CytomX has
strategic drug discovery and development collaborations with
AbbVie, Amgen, Astellas, and Bristol Myers Squibb. The CytomX
clinical-stage pipeline includes potentially first-in-class product
candidates against previously undruggable targets, including a
CD166-targeting Probody drug conjugate wholly owned by CytomX
(CX-2009) and a CD71-targeting Probody drug conjugate partnered
with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that
are considered to be inaccessible to conventional antibody-drug
conjugates due to their presence on many healthy tissues. The
CytomX clinical-stage pipeline also includes cancer
immunotherapeutic candidates against validated targets such as the
CTLA-4-targeting Probody therapeutics, BMS-986249 and BMS-986288,
partnered with Bristol Myers Squibb, and its wholly-owned
anti-PD-L1 Probody therapeutic, CX-072.
Forward-Looking Statements
This press release includes forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other important factors that are difficult to
predict, may be beyond our control, and may cause the actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied in such statements. Accordingly, you should not rely on any
of these forward-looking statements, including statements regarding
the use of proceeds, size, timing or completion of the offering.
Additional applicable risks and uncertainties include those
identified in CytomX’s prospectus supplement filed with the SEC on
January 19, 2021, including the documents incorporated by reference
therein, which include CytomX’s current and future reports filed
with the SEC, including its Quarterly Report on Form 10-Q filed
with the SEC on November 5, 2020. The forward-looking statements
contained in this press release are based on information currently
available to CytomX and speak only as of the date on which they are
made. CytomX does not undertake and specifically disclaims any
obligation to update any forward-looking statements, whether as a
result of any new information, future events, changed circumstances
or otherwise, except as required by law.
Probody is a U.S. registered trademark of CytomX Therapeutics,
Inc.
CytomX Contact:Chau Cheng, PhD
MBAVP, Investor Relations & Corp.
Communicationsccheng@cytomx.com Direct: (650) 273-4999
Investor and Media
Contact:Stern Investor RelationsStephanie
Ascherstephanie.ascher@sternir.com 212-362-1200
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 6 2024 まで 7 2024
CytomX Therapeutics (NASDAQ:CTMX)
過去 株価チャート
から 7 2023 まで 7 2024